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Abstract: Opinion statement
Olanzapine has become a major drug in the management of chemotherapy-induced
nausea and vomiting as a prophylactic agent.  In addition, a recent randomized trial
has demonstrated its benefits in treating nausea and vomiting associated with
advanced cancer.  The added benefit to olanzapine is that it also stimulates appetite.
As a result, since it treats multiple symptoms associated with advanced cancer, it is
likely to become the antiemetic of choice in palliative care at least in the United States.
The added benefit of treating insomnia and the avoidance of benzodiazepines should
place olanzapine in at the top of the list of drugs to use for patients who do complain of
insomnia.  There is no good evidence that it potentiates the respiratory depression of
opioids unlike benzodiazepines.  The evidence is weak that olanzapine in as an
adjuvant analgesic.  Hopefully, future trials will explore this in greater depth.  The
benefits of adding olanzapine to potent opioids is that it may reduce craving, drug cues
and opioid misuse.  Other symptoms like anxiety and depression may be addressed by
the addition of olanzapine to standard antidepressants.
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Olanzapine has become a major drug in the management of chemotherapy-induced nausea and 
vomiting as a prophylactic agent.  In addition, a recent randomized trial has demonstrated its 
benefits in treating nausea and vomiting associated with advanced cancer.  The added benefit 
to olanzapine is that it also stimulates appetite.  As a result, since it treats multiple symptoms 
associated with advanced cancer, it is likely to become the antiemetic of choice in palliative 
care at least in the United States.  The added benefit of treating insomnia and the avoidance of 
benzodiazepines should place olanzapine in at the top of the list of drugs to use for patients 
who do complain of insomnia.  There is no good evidence that it potentiates the respiratory 
depression of opioids unlike benzodiazepines.  The evidence is weak that olanzapine in as an 
adjuvant analgesic.  Hopefully, future trials will explore this in greater depth.  The benefits of 
adding olanzapine to potent opioids is that it may reduce craving, drug cues and opioid misuse.  
Other symptoms like anxiety and depression may be addressed by the addition of olanzapine 




































































Patients with cancer, particularly with advanced cancer, have a multitude of symptoms which 
may not be volunteered without asking [1].  These include anorexia, insomnia, nausea, 
vomiting, pain, constipation, and other symptoms.  The prevalence of nausea and vomiting in 
advanced cancer ranges from 20-30%; 42% of these patients have nausea and/ or vomiting 
without a known ethology [2, 4].  Patients tend to minimize nausea and vomiting, and 
physicians may underestimate its presence [4].  Further, these terms are sometimes combined 
in the literature and often in trials and in the minds of treating clinicians but should be assessed 
separately.  Thus, although nausea and vomiting are strongly associated, they are recognised 
in different areas of the brain and have different sensitivities to different treatments [5].  In 
addition, anorexia and weight loss are two of the most common symptoms and signs of 
advanced cancer which have prognostic importance [6].  Pain is experienced in 50-60% of 
patients with advanced cancer.  Approximately 15% of patients have problems sleeping or have 
clinical insomnia [7].  Finally, substance abuse in patients with cancer occurs in a higher 
prevalence than in the general population.  Multiple cancers are related to tobacco abuse and 
alcohol misuse.  Individuals may also be exposed to opioids or opioid-based medications in a 
higher frequency than the cancer-free population and may have a family risk or personal risk 
for substance abuse [8-10].  These patients require adjuvant medications to help reduce the risk 
and block the cravings that accompany drugs of addiction. 
Because patients receiving palliative care have multiple symptoms, they are often 
exposed to polypharmacy and the risks of drug-drug interactions.  Therefore, medications 
which target multiple symptoms will improve compliance and reduce the risk of drug reactions 
(side-effects) and interactions.  Olanzapine, classified as an atypical antipsychotic, inhibits the 
functions of multiple G protein-coupled and other receptors, and is able to provide a range of 
benefits in palliating patients with advanced cancer. 
Pharmacology of olanzapine 
Olanzapine is a well-established atypical antipsychotic and thienobenzodiazepine, first 
described in1980 [5].  Several studies used radioligand binding to examine the affinity (a 
measure of how strongly the compound binds to the site, expressed as a Ki value in nM) of 
olanzapine for a range of G protein-coupled and other receptors.  Focussing on the human 
targets (usually recombinant), some variability exists in the data from different laboratories, 
but Table 1 provides a summary and an approximate rank order of affinity for the different 
targets.  Following transfection of receptors into host cells, low concentrations of olanzapine 
antagonised at H1, D2, 5-HT2A and 5-HT2B receptors, with higher concentrations antagonising 
at 5-HT2C, 5-HT6, 5-HT7, D3, muscarinic M1, M2, M3 and M4 receptors [11-13]. Later studies 
indicated that olanzapine acted as an inverse agonist at the H1, 5-HT2A, 5-HT2B and 5-HT2C 
receptors, inhibiting function by internalising the receptor [14, 15]. The function of olanzapine 
at the human 5-HT3 receptor has not been demonstrated but the drug antagonised responses to 
activation of this receptor in guinea-pig intestine [12]. However, species differences in 5-HT3 


































































that the effective concentrations of receptor antagonists in guinea-pig or rat functional studies 
do not necessarily translate to human receptor function [16]. 
Olanzapine pharmacokinetics 
Commercially, the preparations include tablets, dissolvable oral discs (zydis) and intramuscular 
preparations which can be given subcutaneous or by intravenous injection [17-21].  Olanzapine 
suppositories have been developed using bases consisting of different compositions of 
Witepsol H-15, Witepsol S-55 for delivery with demonstrated clinical effects but no 
pharmacokinetic data to demonstrate bioavailability [22]. 
There have been no studies on the pharmacokinetics of olanzapine when used as an 
anti-emetic drug (e.g., by intravenous or intramuscular routes during palliative care). 
Nevertheless, studies on oral doses of olanzapine to healthy individuals and psychiatric patients 
help to interpret mechanisms of action (see [23, 24] for detailed descriptions). In summary, 
olanzapine is well absorbed by mouth with bioavailability around 85%.  The half-life of 
olanzapine is 30-60 hours with peak serum concentrations at 4-6 hours [25].  Olanzapine is 
highly metabolized by the liver, primarily through glucuronidation, but also by oxidative 
metabolism to 4’-N desmethyl-olanzapine (via the cytochrome P450 CYP1A2) and 2-
hydroxymethyl-olanzapine (via CYP3A4 [26, 27]).  Plasma concentrations can vary over a 4-
fold range; men show greater clearance and smoking decreases olanzapine concentrations 
(tobacco smoke induces CYP1A2) [28, 29]. Single nucleotide polymorphisms of CYP2D6 can 
also influence olanzapine pharmacokinetics [30]. Notably, olanzapine has no ability to inhibit 
CYP3A, CYP2D6, CYP2C9, or CYP2C19, minimising drug-drug interactions [31]. 
In one study, daily doses of olanzapine (5-30 mg/day) achieved mean plasma 
concentrations from 10 to 54 ng/ml [24]. This suggests good occupancy of H1, 5-HT2A, 5-HT2C, 
5-HT6, 5-HT2B, D2, D4, α2C-adrenoceptor, M4, D1, D3, M5, 5-HT3 and perhaps other receptors 
expressed peripherally. However, a need to penetrate the blood-brain barrier (influenced by 
factors other than passive diffusion) means that higher concentrations are needed to affect the 
receptors expressed within the brain [32].  For example, higher doses of olanzapine are needed 
to access the H1 receptors in the brain (and cause sedation) compared with those needed to 
access other receptors within the periphery (e.g., D2, 5-HT3) and exert anti-emetic activity. 
Summary of mechanisms of the clinical activity of olanzapine 
The side-effects of olanzapine when used as an anti-psychotic medication are described by 
others [33], with the mechanisms summarised in Table 2. 
Of the receptors antagonised by olanzapine, the H1, D2, D3, M4,5 and 5-HT3 receptors 
have a known association with mechanisms of vomiting (Table 2).  A similar involvement of 
5-HT2A receptors remains equivocal [34].  Antagonism at the H1 and M4/5 receptors within the 
brain inhibits motion sickness and possibly other forms of emesis, although the evidence for 
the latter is not clear.  Antagonism at the D2/D3 receptors within the area postrema (a region of 
brain outside the blood-brain barrier) confers a level of general anti-emetic activity, including 
reduction in emesis evoked by anti-cancer agents with low-to-moderate emetogenic potential. 


































































vomiting induced by anti-cancer agents with high emetogenic liability and can also reduce 
post-operative vomiting.  Together, this profile endows a wide spectrum of use for olanzapine, 
which could be an advantage in patients with advanced cancer and potentially, multiple causes 
of nausea and vomiting.  In patients with more well-defined causes of emesis, it is unclear if 
efficacy would be increased by these multiple actions.  In patients receiving highly emetogenic 
chemotherapy co-prescription with dexamethasone and an NK1 receptor antagonist would be 
required. 
The ability of olanzapine to reduce nausea is unclear.  Compared with vomiting, nausea 
remains poorly treated and is associated with activation of brain nuclei concerned with 
interoception (eg. amygdala, putamen, pons, locus coeruleus) and fear conditioning (eg. 
anterior insula and middle cingulate), whereas vomiting is initiated via the so-called vomiting 
centre, a collection of brainstem nuclei [5]. It might appear that a relationship between nausea 
and pathways of interoception is consistent with the hypothesis that the sensations of hunger, 
satiety and nausea and their control by gastrointestinal hormones are interrelated [35-37].  If 
so, then olanzapine could reduce nausea because antagonism at the H1, 5-HT2C and 5-HT2B 
receptors are linked to increased appetite.  Activity at the 5-HT2C, 5-HT2B and the D2 receptor 
may also modulate the activity of ghrelin (Table 2), with implications for appetite control [38, 
39] but not necessarily nausea [40]. 
Olanzapine in The Treatment of Nausea and Vomiting 
Olanzapine has been used effectively as an antiemetic in a multitude of clinical circumstances.  
When reviewing the evidence, it is however, important to understand that nausea is not 
vomiting and can be more difficult to treat [5].  Clinical trial data which do not separate these 
terms (e.g. some describe all events as ‘nausea’) can give a misleading impression of the true 
efficacy of olanzapine and other drugs. 
Postoperative nausea and vomiting. 
The use of chronic atypical antipsychotic therapy, including olanzapine, is associated with 
reduced need for postoperative antiemetic use [41]. In a randomized trial involving women 
undergoing gynaecologic surgery and plastic surgery, the addition of olanzapine 10 mg to 
dexamethasone and ondansetron reduced postoperative nausea and/ or vomiting by 60% 
(primary outcome achieved in 38% versus 14% placebo) with a relative risk for vomiting and/ 
or nausea of 0.37 (95% confidence interval 0.2-0.72, P=0.003) [42] 
Chemotherapy-induced nausea and vomiting 
Olanzapine has been incorporated into guidelines for the treatment of nausea and vomiting 
induced by highly emetogenic chemotherapy (eg. cisplatin), as an effective prophylactic when 
combined with standard ‘triple therapy’ (5-HT3 + NK1 receptor antagonist + dexamethasone) 
and if not used prophylactically, as a rescue antiemetic. The addition of olanzapine is 
recommended because of its ability to further reduce the ‘delayed’ form of emesis in the days 
following the first 24h after treatment (‘acute’ emesis, normally well treated) [43-50].  In one 


































































measured primarily by the absence of vomiting or retching; nausea was reduced on some but 
not all days after treatment [44].  In a retrospective study, olanzapine alone increased the 
incidence of complete remission (no vomiting, nausea, or rescue antiemetics) in patients 
receiving chemotherapy for hematopoietic stem cell transplantation [51].  A systematic review 
of studies centered on stem cell transplantation for myeloma found that olanzapine added to 
standard anti emetics (5-HT3 receptor antagonist with dexamethasone) was superior to the 
addition of an NK1 receptor antagonist [52].  A Bayesian network meta-analysis of 9 
randomized trials and 2959 patients found that in patients receiving highly-emetogenic 
chemotherapy, olanzapine together with dexamethasone and the 5-HT3 receptor antagonist 
palonosetron, produced a greater complete remission rate for acute nausea (odds ratio 3.97), 
delayed nausea (odds ratio 5.62) and overall nausea control (odds ratio 4.79) than 
dexamethasone plus palonosetron alone [53]. In this study and in others [54, 55], the control 
of delayed nausea was equivalent to or superior to the use of an NK1 receptor antagonist.  
Olanzapine has also been found to be superior to metoclopramide in providing rescue for 
breakthrough nausea and vomiting if not used prophylactically [56, 57]. In summary, the 
addition of olanzapine to the standard 3-drug regimen used to prevent chemotherapy-induced 
nausea and vomiting in patients receiving moderate to highly emetogenic chemotherapy, 
further reduces delayed nausea and possibly vomiting [58, 59].  Finally, concerns over the high 
level of sedation associated with the 10 mg dose of olanzapine have led to calls for use of a 
lower dose (5 mg), especially in older patients (over 75 years) and in those who are markedly 
affected by the sedation [60].  It remains to be determined however, if this lower dose retains 
the perceived superiority of olanzapine as a treatment of nausea when combined with standard 
medications. 
Nausea and vomiting with advanced cancer. 
Case reports, case series, prospective studies and a randomized trial have reported benefits 
[e.g., 43, 61-63].  In addition, there are 3 other antiemetics for which randomized trials have 
demonstrated benefit: haloperidol, metoclopramide and methotrimeprazine [64-66]. 
Methotrimeprazine is not available in the United States and produces significant sedation.  
Metoclopramide and haloperidol are associated with an increased risk of extrapyramidal side 
effects relative to olanzapine [67].  Haloperidol is also associated with dose dependent late 
increases in the QTC interval, leading to ventricular arrhythmias [68].  For olanzapine, a recent 
systematic review (13 studies ranging from case reports to retrospective and prospective 
studies) demonstrated significant reduction in vomiting and nausea in advanced cancer 
unrelated to radiation or chemotherapy.  There were no serious adverse events recorded.  
Sedation was the major side effect [69]. 
In a pilot study of patients with advanced cancer and nausea or vomiting of at least 14 
days duration unrelated to radiation in chemotherapy, patients were randomized between 
olanzapine 5 mg daily or placebo plus a rescue antiemetic; the study was over 7 days.  Within 
24 hours of initiating olanzapine, the nausea/ vomiting severity went from 9 (numerical rating 
scale 0-10 with 10 being severe) to 2.  The benefits persisted for the 7 days of the study whereas 
nausea/ vomiting on the placebo arm persisted at 9/10 (P<0.001 between treatment arms).  


































































Olanzapine has been helpful in clinical situations where nausea was difficult to control.  
In a prospective single arm trial, olanzapine 5 mg on average improved nausea and vomiting 
associated with partial bowel obstruction [70].  Patients with nausea and vomiting associated 
with cerebral metastases who have not responded to multiple anti-emetics have responded to 
olanzapine [71-73]. 
Olanzapine and Appetite 
A retrospective review of olanzapine in advanced cancer used pre and post olanzapine in food 
consumption as the main outcome.  Eighty of 951 patients received an average dose of 2.28 
mg per day.  Food consumption increased to 149% (P = 0.001).  In the subset with anorexia 
without nausea, food consumption increased to 143% (P<0.001).  Doses as low as 1.5 mg a 
day increased food consumption 124% (P < 0.01) [74], an interesting finding given the likely 
need for brain penetration by olanzapine in order to affect the central mechanisms controlling 
appetite (Table 2).  In an exploratory randomized trial of different doses of olanzapine (2.5 mg 
to 20 mg daily) in patients with advanced cancer and greater than 10% weight loss, olanzapine 
reduced the slope of weight loss over time; there were no changes in blood levels of leptin, 
total ghrelin or growth hormone although interleukin 6 blood levels increased, possibly because 
of tumor progression [75].  A second randomized trial involving patients with greater than 10% 
body weight loss in advanced cancer, compared thalidomide alone with thalidomide, 
olanzapine and megestrol acetate.  The dose of olanzapine was 5 mg.  Thalidomide was used 
because it may inhibit inflammatory cytokines released in association with anorexia, weight 
loss and sarcopenia.  The combination attenuated weight loss and anorexia compared with 
thalidomide alone, and also reduced sarcopenia measured by mid arm muscle mass [76].  A 
third randomized trial of patients with advanced lung and gastrointestinal cancer compared 
megestrol acetate to olanzapine plus megestrol acetate.  Patients had 5% or greater weight loss 
and anorexia.  The combination improved weight gain (greater than 5%), appetite, nausea and 
quality of life relative to megestrol acetate alone [77].  Finally, a randomized trial of olanzapine 
versus placebo plus antiemetic rescue in patients with cancer and nausea unrelated to 
chemotherapy or radiation, found that olanzapine rapidly reduced nausea and/ or vomiting over 
24 hours but also significantly improved appetite [63]. 
Other actions of olanzapine 
Insomnia 
Olanzapine (5 – 10 mg; average dose 6.67 mg) improved sleep architecture (sleep efficiency, 
total sleep time and sleep latency) in patients with major depression, independent of depression 
responses [78].  In patients with schizophrenia treated with olanzapine 5-25mg daily, the sleep 
architecture was found to be more physiologic than when treated with clozapine [79].  A 
systematic review of the use of antipsychotics, found that olanzapine 5-20 mg in randomized 
trials improved slow wave sleep, had variable effects on REM sleep and reduced sleep latency 
while improving total sleep time [80]. Further, olanzapine 10mg daily, improved recalcitrant 


































































combat post-traumatic stress disorder (5 case reports) improved with olanzapine 10 or 20mg 
[82].  In a small double-blind study, olanzapine 15mg/day, unlike haloperidol 10mg/day, 
treated manic episodes in patients with bipolar disorders, improved sleep efficiency and 
reduced waking after sleep onset [83]  Overall, olanzapine may improve sleep efficiency, total 
sleep time, reduce sleep latency and increase slow wave sleep, unlike other antipsychotics such 
as clozapine, quetiapine, risperidone or haloperidol. The mechanisms are unclear but may be 
related to the ability of olanzapine to cause sedation by antagonism at cortical H1 receptors 
(Table 2). 
Analgesia 
In an animal study olanzapine reduced morphine-induced vomiting and retching as well as the 
thermal hyperalgesia, increased wakefulness and decrease in non-REM sleep associated with 
sciatic nerve lesion [84]. In a mouse tail-flick assay olanzapine had weak anti-nociceptive 
activity, prevented by alpha -2 adrenergic receptor antagonism [85]. 
In a case report, olanzapine 5mg daily improved glossodynia unresponsive to other non-opioid 
analgesics [86].  Some reports suggest that olanzapine was effective in reducing pain from 
disorders such as migraines and fibromyalgia [87].  In a retrospective study of 50 patients with 
refractory headaches unresponsive to at least 4 other therapies, olanzapine 5-35 mg per day 
(average 5-10 mg daily) reduced headache days and the severity of headaches [88].  In 3 case 
studies, olanzapine reduced cervical neck pain from rheumatoid arthritis at doses as low as 
1.25-2.5 mg per day and appeared to be opioid sparing [89].  Olanzapine at doses of 2.5 mg 
has been combined with duloxetine 30 mg to treat chronic pelvic pain [90].  Cancer pain is 
reported to respond to olanzapine with the added benefit of reducing craving.  A patient with 
colon cancer and substance abuse given olanzapine 10 mg at night had reduced craving and 
pain, allowing for reductions in fentanyl doses [91].  A series of 8 patients with severe cancer 
pain despite escalating doses of opioids, responded to olanzapine 2.5-7.5 mg daily, resulting in 
improved cognition, anxiety and stabilizing doses of opioids within 24h of initiating olanzapine 
[92].  In summary, these reports of olanzapine as an analgesic or adjuvant are case reports or 
case series.  Randomized clinical trials are needed to confirm these findings and studies are 
needed to determine the mechanisms of action. 
Delirium 
There is little evidence that antipsychotics in general or olanzapine are helpful in managing 
delirium in advanced cancer.  A comparison of olanzapine to haloperidol found that about half 
of patients responded but responses took longer when patients were treated with olanzapine 
(4.5 days versus 2.8 days) [93].  This study was stopped for futility.  In a systematic review of 
antipsychotics in the management of delirium in terminally ill patients, no difference was found 
in responses between haloperidol and placebo or between olanzapine and haloperidol [94]. 


































































Substance abuse before and after a diagnosis of cancer is not unusual.  Tobacco and alcohol 
abuse are responsible for several cancers.  Individuals with cancer may use illicit substances to 
control symptoms and to cope chemically with their diagnosis.  Opioids are the main analgesics 
used for moderate to severe cancer pain.  Cannabis use during cancer therapy and as treatment 
for symptoms is a growing practice.  It is estimated that 21% of patients with cancer are at high 
risk for substance use and that on average 34% chemically cope with their illness [95]. 
The influence of olanzapine on craving and substance abuse has been explored in 
patients with dual diagnoses (bipolar or schizophrenia plus substance abuse disorder) and in 
the addiction population.  Case series have shown that olanzapine may reduce craving and 
substance abuse in patients with dual diagnoses [e.g., 96-105].  It is suggested that the ability 
of olanzapine to block craving may be related to rapid dissociation from the dopamine D2 
receptor, reducing the risk of dysphoria and super sensitivity to dopamine upon drug 
withdrawal [106, 107], reducing the risk for extrapyramidal symptoms (providing greater 
acceptance and better compliance [108]) and causing a positive mood and improving cognitive 
function, perhaps by antagonism at the different 5-HT receptors and adrenoceptors [106]. 
Even among second generation antipsychotics there are differences.  Quetiapine is 
known on the street as “baby heroin” or “Susie Q” and is a drug of abuse whereas olanzapine 
is known as the “ideal trip terminator/modulator” after a psychedelics drug binge and is known 
to treat unwanted “come-down” symptoms related to drug abuse [109-112].  An open label 
comparison suggested that olanzapine may be as effective as clonidine, if not better in 
managing withdrawal symptoms from heroin [113]. 
Cocaine and Amphetamine Abuse: Several studies reported no benefits of olanzapine in the 
treatment of cocaine dependence [97, 114, 115] but although positive randomized studies exist 
[116] a systematic review concluded that at present, the evidence for beneficial activity was 
weak [117].  Olanzapine reduced the acute psychiatric reactions to amphetamine abuse quicker 
than haloperidol and in rats, pre-treatment with olanzapine prevented conditioned place 
preference related to amphetamines [116, 118]. 
Cannabis Abuse: Olanzapine reduced cannabis craving in patients with a dual diagnosis of 
schizophrenia and cannabis abuse [97].  In a 14-week trial, olanzapine reduced cannabis 
craving in cannabis-dependent individuals [105].  A randomized trial of olanzapine versus 
haloperidol for cannabis psychiatric reactions found both drugs were effective, but olanzapine 
had fewer extrapyramidal side effects [119].  In rats, olanzapine unlike haloperidol, reversed 
the memory deficits and decrease in extracellular ACh levels within the hippocampus caused 
by delta9-tetrahydrocannabinol; the mechanisms of action were unclear [120]. 
Alcohol Abuse: In a series of individuals who were heavy social drinkers, 5 mg of olanzapine 
reduced alcohol-related visual cues but not the rewarding effect of alcohol consumption [103].  
A randomized trial demonstrated that 2.5-5 mg of olanzapine reduced alcohol craving and 
intake, yet a second trial found that olanzapine failed to reduce the relapse rate in individuals 
with an alcohol dependence disorder [121, 122].  The differences in trials may be related to 


































































alcohol intake [122].  In a retrospective study olanzapine with superior to haloperidol in treating 
agitation caused by drugs of abuse including alcohol [123]. 
Nicotine Addiction: In one small study, patients with a dual diagnosis of schizophrenia and 
nicotine abuse were found to have an increase in nicotine use on haloperidol whereas 
olanzapine had no effects [124].  In other studies, olanzapine reduced tobacco or nicotine 
craving and nicotine withdrawal symptoms [101, 125-127]. 
Opioid Abuse: Olanzapine reduced condition place preference in mice exposed to morphine 
[128].  In a randomized trial, olanzapine 10 mg treated opioid withdrawal symptoms more 
effectively than clonidine and in a prospective observational trial, olanzapine reduced the 
dropout rate from opioid maintenance therapy which correlated with a reduction in craving 
[113, 129]. 
Future Directions 
Olanzapine has multiple benefits for patients with advanced cancer.  Not only has it become 
part of the recommended guidelines as prophylaxis for chemotherapy-induced nausea and 
vomiting (reducing the occurrence of delayed nausea/ vomiting), but it can reduce nausea and 
vomiting unrelated to radiation or chemotherapy.  The examples include post-operative nausea 
and vomiting and use in patients with advanced cancer.  The main side-effect is sedation which 
can be minimised by reducing the recommended dose from 10 to 5 mg daily.  Added benefits 
to the use of olanzapine include improved appetite and sleep.  The mechanisms of improved 
appetite are argued to contribute to the mechanisms by which olanzapine may reduce nausea 
(as distinct from vomiting), but trials are needed to determine if this potential advantage is 
maintained at the lower dose of 5mg.  Randomized trials regarding analgesic benefits are 
needed, although the case reports and case series are encouraging.  There is evidence that 
olanzapine as an adjuvant may reduce craving and misuse of multiple drugs that have a risk for 
abuse and addiction but are needed to palliate symptoms of advanced cancer.  Additional 
randomized studies are needed to confirm this. 
Summary 
Olanzapine can antagonise at multiple receptors.  Antagonism at H1, M5 prevents motion 
sickness and may have benefits in treatment of patients with advanced cancer. Antagonism at 
D2/3 prevent mild-to-moderate vomiting evoked by chemotherapy and vomiting evoked by a 
variety of other stimuli. Antagonism at 5-HT3 prevents severe forms of acute emesis induced 
by chemotherapy (notably the first 24h after treatment) and post-operative nausea and 
vomiting. Together, these different actions improve the likelihood of managing vomiting 
during advanced cancer caused by multiple causes.  Olanzapine also increases appetite, acting 
via the H1, 5-HT2B and 5-HT2C receptors; certain of these and other receptors may dimerise 
with the ghrelin receptor and when antagonised, enhance ghrelin release and receptor activity, 
with further promotion of appetite. This type of activity may also inhibit nausea and some 
evidence suggests that olanzapine has superior ability to inhibit late-stage nausea during 


































































10mg may cause sedation (via H1 antagonism), minimised by reducing the dose to 5mg, 
without loss of ability to inhibit chemotherapy-induced vomiting, although trials are needed to 
examine the effects on nausea. These and other actions of olanzapine may also reduce 
insomnia, facilitate analgesic drug activity and prevent different addictions often found among 
patients with advanced cancer and/ or alleviate symptoms of withdrawal. 
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Olanzapine has become a major drug in the management of chemotherapy-induced nausea and 
vomiting as a prophylactic agent.  In addition, a recent randomized trial has demonstrated its 
benefits in treating nausea and vomiting associated with advanced cancer.  The added benefit 
to olanzapine is that it also stimulates appetite.  As a result, since it treats multiple symptoms 
associated with advanced cancer, it is likely to become the antiemetic of choice in palliative 
care at least in the United States.  The added benefit of treating insomnia and the avoidance of 
benzodiazepines should place olanzapine in at the top of the list of drugs to use for patients 
who do complain of insomnia.  There is no good evidence that it potentiates the respiratory 
depression of opioids unlike benzodiazepines.  The evidence is weak that olanzapine in as an 
adjuvant analgesic.  Hopefully, future trials will explore this in greater depth.  The benefits of 
adding olanzapine to potent opioids is that it may reduce craving, drug cues and opioid misuse.  
Other symptoms like anxiety and depression may be addressed by the addition of olanzapine 




































































Patients with cancer, particularly with advanced cancer, have a multitude of symptoms which 
may not be volunteered without asking [1].  These include anorexia, insomnia, nausea, 
vomiting, pain, constipation, and other symptoms.  The prevalence of nausea and vomiting in 
advanced cancer ranges from 20-30%; 42% of these patients have nausea and/ or vomiting 
without a known ethology [2, 4].  Patients tend to minimize nausea and vomiting, and 
physicians may underestimate its presence [4].  Further, these terms are sometimes combined 
in the literature and often in trials and in the minds of treating clinicians but should be assessed 
separately.  Thus, although nausea and vomiting are strongly associated, they are recognised 
in different areas of the brain and have different sensitivities to different treatments [5].  In 
addition, anorexia and weight loss are two of the most common symptoms and signs of 
advanced cancer which have prognostic importance [6].  Pain is experienced in 50-60% of 
patients with advanced cancer.  Approximately 15% of patients have problems sleeping or have 
clinical insomnia [7].  Finally, substance abuse in patients with cancer occurs in a higher 
prevalence than in the general population.  Multiple cancers are related to tobacco abuse and 
alcohol misuse.  Individuals may also be exposed to opioids or opioid-based medications in a 
higher frequency than the cancer-free population and may have a family risk or personal risk 
for substance abuse [8-10].  These patients require adjuvant medications to help reduce the risk 
and block the cravings that accompany drugs of addiction. 
Because patients receiving palliative care have multiple symptoms, they are often 
exposed to polypharmacy and the risks of drug-drug interactions.  Therefore, medications 
which target multiple symptoms will improve compliance and reduce the risk of drug reactions 
(side-effects) and interactions.  Olanzapine, classified as an atypical antipsychotic, inhibits the 
functions of multiple G protein-coupled and other receptors, and is able to provide a range of 
benefits in palliating patients with advanced cancer. 
Pharmacology of olanzapine 
Olanzapine is a well-established atypical antipsychotic and thienobenzodiazepine, first 
described in1980 [5].  Several studies used radioligand binding to examine the affinity (a 
measure of how strongly the compound binds to the site, expressed as a Ki value in nM) of 
olanzapine for a range of G protein-coupled and other receptors.  Focussing on the human 
targets (usually recombinant), some variability exists in the data from different laboratories, 
but Table 1 provides a summary and an approximate rank order of affinity for the different 
targets.  Following transfection of receptors into host cells, low concentrations of olanzapine 
antagonised at H1, D2, 5-HT2A and 5-HT2B receptors, with higher concentrations antagonising 
at 5-HT2C, 5-HT6, 5-HT7, D3, muscarinic M1, M2, M3 and M4 receptors [11-13]. Later studies 
indicated that olanzapine acted as an inverse agonist at the H1, 5-HT2A, 5-HT2B and 5-HT2C 
receptors, inhibiting function by internalising the receptor [14, 15]. The function of olanzapine 
at the human 5-HT3 receptor has not been demonstrated but the drug antagonised responses to 
activation of this receptor in guinea-pig intestine [12]. However, species differences in 5-HT3 


































































that the effective concentrations of receptor antagonists in guinea-pig or rat functional studies 
do not necessarily translate to human receptor function [16]. 
Olanzapine pharmacokinetics 
Commercially, the preparations include tablets, dissolvable oral discs (zydis) and intramuscular 
preparations which can be given subcutaneous or by intravenous injection [17-21].  Olanzapine 
suppositories have been developed using bases consisting of different compositions of 
Witepsol H-15, Witepsol S-55 for delivery with demonstrated clinical effects but no 
pharmacokinetic data to demonstrate bioavailability [22]. 
There have been no studies on the pharmacokinetics of olanzapine when used as an 
anti-emetic drug (e.g., by intravenous or intramuscular routes during palliative care). 
Nevertheless, studies on oral doses of olanzapine to healthy individuals and psychiatric patients 
help to interpret mechanisms of action (see [23, 24] for detailed descriptions). In summary, 
olanzapine is well absorbed by mouth with bioavailability around 85%.  The half-life of 
olanzapine is 30-60 hours with peak serum concentrations at 4-6 hours [25].  Olanzapine is 
highly metabolized by the liver, primarily through glucuronidation, but also by oxidative 
metabolism to 4’-N desmethyl-olanzapine (via the cytochrome P450 CYP1A2) and 2-
hydroxymethyl-olanzapine (via CYP3A4 [26, 27]).  Plasma concentrations can vary over a 4-
fold range; men show greater clearance and smoking decreases olanzapine concentrations 
(tobacco smoke induces CYP1A2) [28, 29]. Single nucleotide polymorphisms of CYP2D6 can 
also influence olanzapine pharmacokinetics [30]. Notably, olanzapine has no ability to inhibit 
CYP3A, CYP2D6, CYP2C9, or CYP2C19, minimising drug-drug interactions [31]. 
In one study, daily doses of olanzapine (5-30 mg/day) achieved mean plasma 
concentrations from 10 to 54 ng/ml [24]. This suggests good occupancy of H1, 5-HT2A, 5-HT2C, 
5-HT6, 5-HT2B, D2, D4, α2C-adrenoceptor, M4, D1, D3, M5, 5-HT3 and perhaps other receptors 
expressed peripherally. However, a need to penetrate the blood-brain barrier (influenced by 
factors other than passive diffusion) means that higher concentrations are needed to affect the 
receptors expressed within the brain [32].  For example, higher doses of olanzapine are needed 
to access the H1 receptors in the brain (and cause sedation) compared with those needed to 
access other receptors within the periphery (e.g., D2, 5-HT3) and exert anti-emetic activity. 
Summary of mechanisms of the clinical activity of olanzapine 
The side-effects of olanzapine when used as an anti-psychotic medication are described by 
others [33], with the mechanisms summarised in Table 2. 
Of the receptors antagonised by olanzapine, the H1, D2, D3, M4,5 and 5-HT3 receptors 
have a known association with mechanisms of vomiting (Table 2).  A similar involvement of 
5-HT2A receptors remains equivocal [34].  Antagonism at the H1 and M4/5 receptors within the 
brain inhibits motion sickness and possibly other forms of emesis, although the evidence for 
the latter is not clear.  Antagonism at the D2/D3 receptors within the area postrema (a region of 
brain outside the blood-brain barrier) confers a level of general anti-emetic activity, including 
reduction in emesis evoked by anti-cancer agents with low-to-moderate emetogenic potential. 


































































vomiting induced by anti-cancer agents with high emetogenic liability and can also reduce 
post-operative vomiting.  Together, this profile endows a wide spectrum of use for olanzapine, 
which could be an advantage in patients with advanced cancer and potentially, multiple causes 
of nausea and vomiting.  In patients with more well-defined causes of emesis, it is unclear if 
efficacy would be increased by these multiple actions.  In patients receiving highly emetogenic 
chemotherapy co-prescription with dexamethasone and an NK1 receptor antagonist would be 
required. 
The ability of olanzapine to reduce nausea is unclear.  Compared with vomiting, nausea 
remains poorly treated and is associated with activation of brain nuclei concerned with 
interoception (eg. amygdala, putamen, pons, locus coeruleus) and fear conditioning (eg. 
anterior insula and middle cingulate), whereas vomiting is initiated via the so-called vomiting 
centre, a collection of brainstem nuclei [5]. It might appear that a relationship between nausea 
and pathways of interoception is consistent with the hypothesis that the sensations of hunger, 
satiety and nausea and their control by gastrointestinal hormones are interrelated [35-37].  If 
so, then olanzapine could reduce nausea because antagonism at the H1, 5-HT2C and 5-HT2B 
receptors are linked to increased appetite.  Activity at the 5-HT2C, 5-HT2B and the D2 receptor 
may also modulate the activity of ghrelin (Table 2), with implications for appetite control [38, 
39] but not necessarily nausea [40]. 
Olanzapine in The Treatment of Nausea and Vomiting 
Olanzapine has been used effectively as an antiemetic in a multitude of clinical circumstances.  
When reviewing the evidence, it is however, important to understand that nausea is not 
vomiting and can be more difficult to treat [5].  Clinical trial data which do not separate these 
terms (e.g. some describe all events as ‘nausea’) can give a misleading impression of the true 
efficacy of olanzapine and other drugs. 
Postoperative nausea and vomiting. 
The use of chronic atypical antipsychotic therapy, including olanzapine, is associated with 
reduced need for postoperative antiemetic use [41]. In a randomized trial involving women 
undergoing gynaecologic surgery and plastic surgery, the addition of olanzapine 10 mg to 
dexamethasone and ondansetron reduced postoperative nausea and/ or vomiting by 60% 
(primary outcome achieved in 38% versus 14% placebo) with a relative risk for vomiting and/ 
or nausea of 0.37 (95% confidence interval 0.2-0.72, P=0.003) [42] 
Chemotherapy-induced nausea and vomiting 
Olanzapine has been incorporated into guidelines for the treatment of nausea and vomiting 
induced by highly emetogenic chemotherapy (eg. cisplatin), as an effective prophylactic when 
combined with standard ‘triple therapy’ (5-HT3 + NK1 receptor antagonist + dexamethasone) 
and if not used prophylactically, as a rescue antiemetic. The addition of olanzapine is 
recommended because of its ability to further reduce the ‘delayed’ form of emesis in the days 
following the first 24h after treatment (‘acute’ emesis, normally well treated) [43-50].  In one 


































































measured primarily by the absence of vomiting or retching; nausea was reduced on some but 
not all days after treatment [44].  In a retrospective study, olanzapine alone increased the 
incidence of complete remission (no vomiting, nausea, or rescue antiemetics) in patients 
receiving chemotherapy for hematopoietic stem cell transplantation [51].  A systematic review 
of studies centered on stem cell transplantation for myeloma found that olanzapine added to 
standard anti emetics (5-HT3 receptor antagonist with dexamethasone) was superior to the 
addition of an NK1 receptor antagonist [52].  A Bayesian network meta-analysis of 9 
randomized trials and 2959 patients found that in patients receiving highly-emetogenic 
chemotherapy, olanzapine together with dexamethasone and the 5-HT3 receptor antagonist 
palonosetron, produced a greater complete remission rate for acute nausea (odds ratio 3.97), 
delayed nausea (odds ratio 5.62) and overall nausea control (odds ratio 4.79) than 
dexamethasone plus palonosetron alone [53]. In this study and in others [54, 55], the control 
of delayed nausea was equivalent to or superior to the use of an NK1 receptor antagonist.  
Olanzapine has also been found to be superior to metoclopramide in providing rescue for 
breakthrough nausea and vomiting if not used prophylactically [56, 57]. In summary, the 
addition of olanzapine to the standard 3-drug regimen used to prevent chemotherapy-induced 
nausea and vomiting in patients receiving moderate to highly emetogenic chemotherapy, 
further reduces delayed nausea and possibly vomiting [58, 59].  Finally, concerns over the high 
level of sedation associated with the 10 mg dose of olanzapine have led to calls for use of a 
lower dose (5 mg), especially in older patients (over 75 years) and in those who are markedly 
affected by the sedation [60].  It remains to be determined however, if this lower dose retains 
the perceived superiority of olanzapine as a treatment of nausea when combined with standard 
medications. 
Nausea and vomiting with advanced cancer. 
Case reports, case series, prospective studies and a randomized trial have reported benefits 
[e.g., 43, 61-63].  In addition, there are 3 other antiemetics for which randomized trials have 
demonstrated benefit: haloperidol, metoclopramide and methotrimeprazine [64-66]. 
Methotrimeprazine is not available in the United States and produces significant sedation.  
Metoclopramide and haloperidol are associated with an increased risk of extrapyramidal side 
effects relative to olanzapine [67].  Haloperidol is also associated with dose dependent late 
increases in the QTC interval, leading to ventricular arrhythmias [68]. Olanzapine  as assessed 
in five meta-analyses and twenty RCTs does not increase the QT interval1  For olanzapine, a 
recent systematic review (13 studies ranging from case reports to retrospective and prospective 
studies) demonstrated significant reduction in vomiting and nausea in advanced cancer 
unrelated to radiation or chemotherapy.  There were no serious adverse events recorded.  
Sedation was the major side effect [69]. 
In a pilot study of patients with advanced cancer and nausea or vomiting of at least 14 
days duration unrelated to radiation in chemotherapy, patients were randomized between 
olanzapine 5 mg daily or placebo plus a rescue antiemetic; the study was over 7 days.  Within 
24 hours of initiating olanzapine, the nausea/ vomiting severity went from 9 (numerical rating 


































































nausea/ vomiting on the placebo arm persisted at 9/10 (P<0.001 between treatment arms).  
Olanzapine also improved appetite, fatigue and well-being [43]. 
Olanzapine has been helpful in clinical situations where nausea was difficult to control.  
In a prospective single arm trial, olanzapine 5 mg on average improved nausea and vomiting 
associated with partial bowel obstruction [70].  Patients with nausea and vomiting associated 
with cerebral metastases who have not responded to multiple anti-emetics have responded to 
olanzapine [71-73]. 
Olanzapine and Appetite 
A retrospective review of olanzapine in advanced cancer used pre and post olanzapine in food 
consumption as the main outcome.  Eighty of 951 patients received an average dose of 2.28 
mg per day.  Food consumption increased to 149% (P = 0.001).  In the subset with anorexia 
without nausea, food consumption increased to 143% (P<0.001).  Doses as low as 1.5 mg a 
day increased food consumption 124% (P < 0.01) [74], an interesting finding given the likely 
need for brain penetration by olanzapine in order to affect the central mechanisms controlling 
appetite (Table 2).  In an exploratory randomized trial of different doses of olanzapine (2.5 mg 
to 20 mg daily) in patients with advanced cancer and greater than 10% weight loss, olanzapine 
reduced the slope of weight loss over time; there were no changes in blood levels of leptin, 
total ghrelin or growth hormone although interleukin 6 blood levels increased, possibly because 
of tumor progression [75].  A second randomized trial involving patients with greater than 10% 
body weight loss in advanced cancer, compared thalidomide alone with thalidomide, 
olanzapine and megestrol acetate.  The dose of olanzapine was 5 mg.  Thalidomide was used 
because it may inhibit inflammatory cytokines released in association with anorexia, weight 
loss and sarcopenia.  The combination attenuated weight loss and anorexia compared with 
thalidomide alone, and also reduced sarcopenia measured by mid arm muscle mass [76].  A 
third randomized trial of patients with advanced lung and gastrointestinal cancer compared 
megestrol acetate to olanzapine plus megestrol acetate.  Patients had 5% or greater weight loss 
and anorexia.  The combination improved weight gain (greater than 5%), appetite, nausea and 
quality of life relative to megestrol acetate alone [77].  Finally, a randomized trial of olanzapine 
versus placebo plus antiemetic rescue in patients with cancer and nausea unrelated to 
chemotherapy or radiation, found that olanzapine rapidly reduced nausea and/ or vomiting over 
24 hours but also significantly improved appetite [63]. 
Other actions of olanzapine 
Insomnia 
Olanzapine (5 – 10 mg; average dose 6.67 mg) improved sleep architecture (sleep efficiency, 
total sleep time and sleep latency) in patients with major depression, independent of depression 
responses [78].  In patients with schizophrenia treated with olanzapine 5-25mg daily, the sleep 
architecture was found to be more physiologic than when treated with clozapine [79].  A 
systematic review of the use of antipsychotics, found that olanzapine 5-20 mg in randomized 


































































while improving total sleep time [80]. Further, olanzapine 10mg daily, improved recalcitrant 
paradoxical insomnia whereas risperidone had little effect [81].  Insomnia associated with 
combat post-traumatic stress disorder (5 case reports) improved with olanzapine 10 or 20mg 
[82].  In a small double-blind study, olanzapine 15mg/day, unlike haloperidol 10mg/day, 
treated manic episodes in patients with bipolar disorders, improved sleep efficiency and 
reduced waking after sleep onset [83]  Overall, olanzapine may improve sleep efficiency, total 
sleep time, reduce sleep latency and increase slow wave sleep, unlike other antipsychotics such 
as clozapine, quetiapine, risperidone or haloperidol. The mechanisms are unclear but may be 
related to the ability of olanzapine to cause sedation by antagonism at cortical H1 receptors 
(Table 2). 
Analgesia 
In an animal study olanzapine reduced morphine-induced vomiting and retching as well as the 
thermal hyperalgesia, increased wakefulness and decrease in non-REM sleep associated with 
sciatic nerve lesion [84]. In a mouse tail-flick assay olanzapine had weak anti-nociceptive 
activity, prevented by alpha -2 adrenergic receptor antagonism [85]. 
In a case report, olanzapine 5mg daily improved glossodynia unresponsive to other non-opioid 
analgesics [86].  Some reports suggest that olanzapine was effective in reducing pain from 
disorders such as migraines and fibromyalgia [87].  In a retrospective study of 50 patients with 
refractory headaches unresponsive to at least 4 other therapies, olanzapine 5-35 mg per day 
(average 5-10 mg daily) reduced headache days and the severity of headaches [88].  In 3 case 
studies, olanzapine reduced cervical neck pain from rheumatoid arthritis at doses as low as 
1.25-2.5 mg per day and appeared to be opioid sparing [89].  Olanzapine at doses of 2.5 mg 
has been combined with duloxetine 30 mg to treat chronic pelvic pain [90].  Cancer pain is 
reported to respond to olanzapine with the added benefit of reducing craving.  A patient with 
colon cancer and substance abuse given olanzapine 10 mg at night had reduced craving and 
pain, allowing for reductions in fentanyl doses [91].  A series of 8 patients with severe cancer 
pain despite escalating doses of opioids, responded to olanzapine 2.5-7.5 mg daily, resulting in 
improved cognition, anxiety and stabilizing doses of opioids within 24h of initiating olanzapine 
[92].  In summary, these reports of olanzapine as an analgesic or adjuvant are case reports or 
case series.  Randomized clinical trials are needed to confirm these findings and studies are 
needed to determine the mechanisms of action. 
Delirium 
There is little evidence that antipsychotics in general or olanzapine are helpful in managing 
delirium in advanced cancer.  A comparison of olanzapine to haloperidol found that about half 
of patients responded but responses took longer when patients were treated with olanzapine 
(4.5 days versus 2.8 days) [93].  This study was stopped for futility.  In a systematic review of 
antipsychotics in the management of delirium in terminally ill patients, no difference was found 
in responses between haloperidol and placebo or between olanzapine and haloperidol [94]. 


































































Substance abuse before and after a diagnosis of cancer is not unusual.  Tobacco and alcohol 
abuse are responsible for several cancers.  Individuals with cancer may use illicit substances to 
control symptoms and to cope chemically with their diagnosis.  Opioids are the main analgesics 
used for moderate to severe cancer pain.  Cannabis use during cancer therapy and as treatment 
for symptoms is a growing practice.  It is estimated that 21% of patients with cancer are at high 
risk for substance use and that on average 34% chemically cope with their illness [95]. 
The influence of olanzapine on craving and substance abuse has been explored in 
patients with dual diagnoses (bipolar or schizophrenia plus substance abuse disorder) and in 
the addiction population.  Case series have shown that olanzapine may reduce craving and 
substance abuse in patients with dual diagnoses [e.g., 96-105].  It is suggested that the ability 
of olanzapine to block craving may be related to rapid dissociation from the dopamine D2 
receptor, reducing the risk of dysphoria and super sensitivity to dopamine upon drug 
withdrawal [106, 107], reducing the risk for extrapyramidal symptoms (providing greater 
acceptance and better compliance [108]) and causing a positive mood and improving cognitive 
function, perhaps by antagonism at the different 5-HT receptors and adrenoceptors [106]. 
Even among second generation antipsychotics there are differences.  Quetiapine is 
known on the street as “baby heroin” or “Susie Q” and is a drug of abuse whereas olanzapine 
is known as the “ideal trip terminator/modulator” after a psychedelics drug binge and is known 
to treat unwanted “come-down” symptoms related to drug abuse [109-112].  An open label 
comparison suggested that olanzapine may be as effective as clonidine, if not better in 
managing withdrawal symptoms from heroin [113]. 
Cocaine and Amphetamine Abuse: Several studies reported no benefits of olanzapine in the 
treatment of cocaine dependence [97, 114, 115] but although positive randomized studies exist 
[116] a systematic review concluded that at present, the evidence for beneficial activity was 
weak [117].  Olanzapine reduced the acute psychiatric reactions to amphetamine abuse quicker 
than haloperidol and in rats, pre-treatment with olanzapine prevented conditioned place 
preference related to amphetamines [116, 118]. 
Cannabis Abuse: Olanzapine reduced cannabis craving in patients with a dual diagnosis of 
schizophrenia and cannabis abuse [97].  In a 14-week trial, olanzapine reduced cannabis 
craving in cannabis-dependent individuals [105].  A randomized trial of olanzapine versus 
haloperidol for cannabis psychiatric reactions found both drugs were effective, but olanzapine 
had fewer extrapyramidal side effects [119].  In rats, olanzapine unlike haloperidol, reversed 
the memory deficits and decrease in extracellular ACh levels within the hippocampus caused 
by delta9-tetrahydrocannabinol; the mechanisms of action were unclear [120]. 
Alcohol Abuse: In a series of individuals who were heavy social drinkers, 5 mg of olanzapine 
reduced alcohol-related visual cues but not the rewarding effect of alcohol consumption [103].  
A randomized trial demonstrated that 2.5-5 mg of olanzapine reduced alcohol craving and 
intake, yet a second trial found that olanzapine failed to reduce the relapse rate in individuals 
with an alcohol dependence disorder [121, 122].  The differences in trials may be related to 


































































alcohol intake [122].  In a retrospective study olanzapine with superior to haloperidol in treating 
agitation caused by drugs of abuse including alcohol [123]. 
Nicotine Addiction: In one small study, patients with a dual diagnosis of schizophrenia and 
nicotine abuse were found to have an increase in nicotine use on haloperidol whereas 
olanzapine had no effects [124].  In other studies, olanzapine reduced tobacco or nicotine 
craving and nicotine withdrawal symptoms [101, 125-127]. 
Opioid Abuse: Olanzapine reduced condition place preference in mice exposed to morphine 
[128].  In a randomized trial, olanzapine 10 mg treated opioid withdrawal symptoms more 
effectively than clonidine and in a prospective observational trial, olanzapine reduced the 
dropout rate from opioid maintenance therapy which correlated with a reduction in craving 
[113, 129]. 
Future Directions 
Olanzapine has multiple benefits for patients with advanced cancer.  Not only has it become 
part of the recommended guidelines as prophylaxis for chemotherapy-induced nausea and 
vomiting (reducing the occurrence of delayed nausea/ vomiting), but it can reduce nausea and 
vomiting unrelated to radiation or chemotherapy.  The examples include post-operative nausea 
and vomiting and use in patients with advanced cancer.  The main side-effect is sedation which 
can be minimised by reducing the recommended dose from 10 to 5 mg daily.  Added benefits 
to the use of olanzapine include improved appetite and sleep.  The mechanisms of improved 
appetite are argued to contribute to the mechanisms by which olanzapine may reduce nausea 
(as distinct from vomiting), but trials are needed to determine if this potential advantage is 
maintained at the lower dose of 5mg.  Randomized trials regarding analgesic benefits are 
needed, although the case reports and case series are encouraging.  There is evidence that 
olanzapine as an adjuvant may reduce craving and misuse of multiple drugs that have a risk for 
abuse and addiction but are needed to palliate symptoms of advanced cancer.  Additional 
randomized studies are needed to confirm this. 
Summary 
Olanzapine can antagonise at multiple receptors.  Antagonism at H1, M5 prevents motion 
sickness and may have benefits in treatment of patients with advanced cancer. Antagonism at 
D2/3 prevent mild-to-moderate vomiting evoked by chemotherapy and vomiting evoked by a 
variety of other stimuli. Antagonism at 5-HT3 prevents severe forms of acute emesis induced 
by chemotherapy (notably the first 24h after treatment) and post-operative nausea and 
vomiting. Together, these different actions improve the likelihood of managing vomiting 
during advanced cancer caused by multiple causes.  Olanzapine also increases appetite, acting 
via the H1, 5-HT2B and 5-HT2C receptors; certain of these and other receptors may dimerise 
with the ghrelin receptor and when antagonised, enhance ghrelin release and receptor activity, 
with further promotion of appetite. This type of activity may also inhibit nausea and some 
evidence suggests that olanzapine has superior ability to inhibit late-stage nausea during 


































































10mg may cause sedation (via H1 antagonism), minimised by reducing the dose to 5mg, 
without loss of ability to inhibit chemotherapy-induced vomiting, although trials are needed to 
examine the effects on nausea. These and other actions of olanzapine may also reduce 
insomnia, facilitate analgesic drug activity and prevent different addictions often found among 
patients with advanced cancer and/ or alleviate symptoms of withdrawal. 
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Table 1: Summary and rank order of affinity of olanzapine for human receptor targets. 
H1 (0.7-2.8 nM) > 5-HT2A (2-24), 5-HT2C (6-14), 5-HT6 (6.3-10) > 5-HT2B (12) > D2 (20-78), 
D4 (28-60), α2C-adrenoceptor (29-210), M4 (32), D1 (35-118) > D3 (43-49), M5 (48), 5-HT3 
(57) > M1 (73), D5 (74), α2B-adrenoceptor (82-180), M2 (96) > M3 (105-132), 5-HT7 (105-
365), α1A-adrenoceptor (115) > α2A-adrenoceptor (192-470), 5-HT1F (310). 
Beginning with the receptor with highest affinity for olanzapine, the range of values in 
parenthesis are the Ki’s in nM [1-7]. The values for the muscarinic receptors were obtained 
using intact cell preparations [8]. The value for 5-HT3 is for the rat receptor [9]. 
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Caused by antagonism at D2 receptors within the nigrostriatal dopamine system of the brain. Although olanzapine is a brain 
penetrant D2 receptor antagonist, when compared with ‘early’ anti-psychotic drugs (e.g. chlorpromazine, haloperidol), the drug 
has a low propensity to cause extrapyramidal effects or sustained increases in prolactin levels. This may be explained by 
differences in the rates of drug-receptor association and dissociation during competition with endogenous dopamine [1], 
although it has been argued that the higher affinity of olanzapine for 5-HT2A and 5-HT2C receptors may also confer opposing 
effects [2, 3]. 
Sedation 
 




Associated with hyperphagia and antagonism at the H1 and 5-HT2C receptors [5-7]; in rat brain, continuous use of olanzapine 
may change H1 receptor and histidine decarboxylase expression in a manner positively correlated with increased food intake 
[8]. 
Dry mouth and 
constipation 
Associated with antagonism at M3 and in addition, M1 and M2 receptors which in the bowel, slows intestinal movements [9]. 
VOMITING 
H1, M5 H1 receptors are involved in mechanisms of vomiting induced by abnormal motion. In this activity the receptors are located in 
the vestibular system and in the brainstem integrative circuitry which coordinates the different pathways needed to initiate 
vomiting (often referred to as the ‘vomiting centre‘) [10-12].  Motion sickness can also be controlled by muscarinic receptor 
antagonists acting primarily at M5 receptors in the vestibular nucleus.  It is possible that simultaneous antagonism of H1 and 
the muscarinic receptors provides greater protection against motion sickness than H1 receptor antagonism alone [12].  
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Interestingly, the well-established anti-emetic drug cyclizine, is an antagonist at H1 and muscarinic receptors [13] and is used 
to manage nausea and vomiting in other conditions (e.g. in cancer patients during palliative care), indicating a need to further 
explore the spectrum of anti-emetic activity created by a combination of antagonism at these receptors. 
D2/3 Dopamine D2 receptor antagonists are anti-emetic because they block D2 receptors within the area postrema (often called the 
‘chemosensitive trigger zone’), a densely vascularized circumventricular organ at the caudal extremity of the fourth ventricle, 
where the blood-brain and cerebrospinal fluid-brain barriers are relatively permeable. This exposes neurons in the perivascular 
sheaths of the capillaries to small and large molecules in the blood and cerebrospinal fluid [14].  Although dopamine and D2-
like  receptor binding sites have been detected within the human area postrema [15] little is known about the mechanism by 
which dopamine is released or what represents the circulating emetic stimulus; adrenaline, glucagon-like peptide-1 and 
cholecystokinin are examples of possibilities [13]. The D3 receptor may also be involved in the mechanisms of vomiting.  
Compared with the D2 receptor, this receptor appears to be more homogenously expressed across the brainstem areas which 
constitute the ‘vomiting centre’ (nucleus tractus solitarius, area postrema, dorsal motor nucleus [16]. Selective D3 receptor 
agonists cause vomiting in dogs and ferrets by acting at least in part within the area postrema [17, 18]. Experiments in shrews 
suggests a functional interaction between D2 and D3 receptors such that an antagonist at both receptors might be superior to an 
antagonist at D2 alone [19]. D1 and D4 receptor agonists do not cause vomiting [17, 20]. 
5-HT3 5-HT3 receptors are synthesized within the cell bodies of vagal nerves and are transported to the central and peripheral terminals.  
The vagus (the Xth cranial nerve) projects over the pelvic, visceral and thoracic structures (the name is derived from the Latin 
for ‘wanderer’ with the majority of axons innervating the abdomen consisting of unmyelinated afferent C-fibres [21].  In terms 
of the vomiting caused by anti-cancer chemotherapy, 5-HT is released from the large store contained within enterochromaffin 
cells of the duodenum to activate adjacent vagal nerve terminals and sensitise the terminals to excitation by other excitatory 
substances, resulting in sustained activation [22]. The abdominal vagal terminals project mostly to the nucleus tractus solitarius 
(NTS) of the brainstem which in turn projects to the different brainstem nuclei which initiate the different motor components 
of vomiting [23].  Activation of 5-HT3 receptors on the central terminals of the vagus nerve (by circulating 5-HT for example) 
remains a possibility but their pathophysiological significance remains unclear [22, 24]. 
NAUSEA 
Inhibition of 







Antagonism of the functions of each of these receptors are linked to increased appetite and if appetite and nausea are 
interrelated, then it might be anticipated that olanzapine could reduce nausea. In support of this argument, nausea was a common 
side-effect of the 5-HT2C receptor agonist lorcaserin, used to reduce food consumption and treat obesity [25, 26]. In addition, 
some studies have linked the actions of H1, 5-HT2B, 5-HT2C and D2 receptors with the release and actions of acylated ghrelin 
(the form of ghrelin which unlike the des-acylated form, activates the ghrelin receptor). Decreased plasma concentrations of 
total ghrelin are associated with nausea and vomiting [27] and ghrelin or ghrelin receptor agonists reduce cachexia in cancer 
patients [28], severity of vomiting and other symptoms in patients with gastroparesis [29] and alleviate anorexia and vomiting 
in animal models of dyspepsia and vomiting [30-32].  In the rat, a non-vomiting species without proven ability to experience 
nausea [13], chemotherapy (treatment with cisplatin) reduced secretion of acylated ghrelin by a mechanism mimicked by 5-
HT2B or 5-HT2C receptor agonists and reversed by antagonism at these receptors (suggesting that cisplatin-induced release of 
5-HT from GI enterochromaffin cells could directly inhibit ghrelin release from the stomach) and ghrelin secretion increased 
when a 5-HT2C receptor antagonist was given alone [33, 34].  In HEK293 cells, 5-HT2C receptor antagonism may reverse 
attenuation of ghrelin receptor function caused by 5-HT2C receptor-mediated heterodimerization of transfected ghrelin and 5-
HT2C receptors and their subsequent internalization [35].  In the mouse hypothalamus, the H1 and ghrelin receptor may also 
dimerize, a process disrupted by olanzapine, leading to increased ghrelin signalling and neuropeptide-Y release to increase 
appetite [36].  The D2 and ghrelin receptors can dimerize in the mouse hypothalamus [37], potentially relevant to mechanisms 
of vomiting.  Interestingly, in patients with cancer and lack of appetite the ratio of acylated to desacylated ghrelin was low [38] 
and in patients with schizophrenia treated with olanzapine, those with the better metabolic syndrome profiles had lower 
acylated/ des-acylated ratios [39]. Finally, relatively high concentrations of olanzapine (but not haloperidol) increased the 
ability of ghrelin to activate its receptor when transfected into a host cell [40]; the pathophysiological relevance of this 
observation is unknown. 
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